United States

People: Cree Inc (CREE.O)

CREE.O on Nasdaq

18 Aug 2017
Change (% chg)

$-0.20 (-0.87%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Ingram, Robert 

Mr. Robert A. Ingram is Lead Independent Director of the company. Mr. Ingram joined the Board of Directors in December 2008 and has served as Lead Independent Director since October 2011. Since January 2007, he has been a General Partner in Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies in the southeast United States, and he has also served as strategic advisor to the chief executive officer of GlaxoSmithKline plc, a publicly traded pharmaceutical research and development company. From 2003 through 2009, he served as Vice Chairman Pharmaceuticals, GlaxoSmithKline. He previously served as Chief Operating Officer and President of Pharmaceutical Operations of GlaxoSmithKline following the December 2000 merger of Glaxo Wellcome plc and SmithKline Beecham plc. Prior to the merger he served as Chief Executive Officer of Glaxo Wellcome plc and as Chairman, President and Chief Executive Officer of Glaxo Wellcome Inc. Mr. Ingram also serves on the Board of Directors of Edwards Lifesciences Corporation and Regeneron Pharmaceuticals, Inc., and serves as Lead Director of Valeant Pharmaceuticals International, Inc. He also served as Chairman of the Board of Directors of OSI Pharmaceuticals, Inc. from January 2003 until its sale in June 2010, and served on the Board of Directors of Elan Corporation, plc from December 2010 until its sale in December 2013 and as its Chairman from January 2011 until December 2013. He previously served as a director of Misys plc, Nortel Networks Corp., Wachovia Corp., Lowe’s Companies, Inc., Pharmaceutical Product Development, Inc. and Allergan, Inc. until 2005, 2006, 2008, May 2011, December 2011 and December 2012, respectively.

Basic Compensation

Total Annual Compensation, USD 62,500
Restricted Stock Awards, USD 28,846
Long-Term Incentive Plans, USD --
All Other, USD 77,281
Fiscal Year Total, USD 168,627

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Charles Swoboda


Michael McDevitt


Norbert Hiller


Robert Ingram


John Replogle


Alan Ruud

As Of  28 Jun 2014